Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ivonescimab with SBRT and Chemotherapy in Pancreatic Cancer
NCT06491472Phase 2Recruiting
- Start
- Jul 2024
- Primary completion
- Jul 2026
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ivonescimab in pancreatic ductal adenocarcinoma (PDAC). Primary endpoint: Objective Response Rate at 2 years. Started Jul 2024; status: recruiting.
02
Drugs
ivonescimab
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT06491472.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06491472.